Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.

Siqing FuBradley R CorrKerry Culm-MerdekColleen MockbeeHagop YoussoufianRobert StaggR Wendel Naumann Robert M Wenham Rafael D RosengartenLaura BenjaminErika Paige Hamilton Kathleen M Moore

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity.

Keyphrases

papillary thyroid
squamous cell
hiv infected
lymph node metastasis
chemotherapy induced
young adults
newly diagnosed
antiretroviral therapy